International Journal of Microbiology

International Journal of Microbiology / 2016 / Article

Letter to the Editor | Open Access

Volume 2016 |Article ID 6304150 |

Amin Talebi Bezmin Abadi, "Comment on “Bacteria in Cancer Therapy: Renaissance of an Old Concept”", International Journal of Microbiology, vol. 2016, Article ID 6304150, 1 page, 2016.

Comment on “Bacteria in Cancer Therapy: Renaissance of an Old Concept”

Academic Editor: Todd R. Callaway
Received03 May 2016
Accepted09 Aug 2016
Published14 Sep 2016

Felgner et al. published an outstanding article reporting the bacteria as a novel approach to target cancer therapy to overcome current limitations of conventional therapies [1]. Lack of compliance to conventional anticancer treatments has prompted a call for alternative options [2, 3]. The possibility of using bacteria in cancer therapy has been determined many years ago [4]. At the moment, we do not recommend starting using this method as clinical solution for tumor or even other diseases. Taken together, some points we found may not support the proposed approach. It has been called a novel approach while still there are many pitfalls in application of bacteria because of their toxicity and deleterious side effects. For example, due to the intrinsic genetic instability of certain bacteria such as Bifidobacterium longum and Escherichia coli, there is no certainty about sufficient and consistent effect of this kind of therapy in long term of treatment. To date, we know that bacterial plasmid can be easily lost after a generation in human body; conclusively, our therapy can be quickly hampered. Notably, new genetic technology can help to reduce available problems but in close future. In vivo results had shown a relative success but more investigation regarding the targets that the bacteria should go for is necessary to provide a brilliant approach in cancer therapy. In other words, we are still in early ages to draw such an optimistic dream against various persistent tumors! Relatively high toxicity chance is the major difficulty with using bacteria as anticancer agents, a problem which needs different clinical trials with long-term follow-up. Notably, this problem can be even exacerbated if the used bacterium contains a potential to work as systemic microbe; then, occurrence of septicemia would be another obstacle. Last but not least, bacterial therapy will be even more expensive than other conventional treatments. As such, better suitable approaches should be recommended.


The content of this article is the sole responsibility of the author and necessarily represents personal prospective. Moreover, the funding agencies had no role in the decision to publish or the preparation of the paper.

Competing Interests

The author has declared that no competing interests exist.


  1. S. Felgner, D. Kocijancic, M. Frahm, and S. Weiss, “Bacteria in cancer therapy: renaissance of an old concept,” International Journal of Microbiology, vol. 2016, Article ID 8451728, 14 pages, 2016. View at: Publisher Site | Google Scholar
  2. K. K. Jain, “Use of bacteria as anticancer agents,” Expert Opinion on Biological Therapy, vol. 1, no. 2, pp. 291–300, 2001. View at: Publisher Site | Google Scholar
  3. A. T. B. Abadi, “Therapy of Helicobacter pylori: present medley and future prospective,” BioMed Research International, vol. 2014, Article ID 124607, 7 pages, 2014. View at: Publisher Site | Google Scholar
  4. I. Lokody, “Anticancer therapy: bacterial treatment for cancer,” Nature Reviews Drug Discovery, vol. 13, no. 10, article 726, 2014. View at: Publisher Site | Google Scholar

Copyright © 2016 Amin Talebi Bezmin Abadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.